FDA accepts Corcept's NDA for relacorilant in Cushing's syndrome; PDUFA Dec 30, 2025

CORCEPT THERAPEUTICS INC

FDA filed relacorilant NDA for endogenous hypercortisolism (Cushing's syndrome).
PDUFA target action date set for December 30, 2025.
NDA supported by positive GRACE, GRADIENT, and Phase 2 trial results.
No drug-induced adrenal insufficiency, hypokalemia, or QT prolongation observed in trials.
CEO states relacorilant has potential to become new standard of care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.